BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yilmaz Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther. 2012;36:815-823. [PMID: 22966992 DOI: 10.1111/apt.12046] [Cited by in Crossref: 119] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Ke Z, Zhao Y, Tan S, Chen H, Li Y, Zhou Z, Huang C. Citrus reticulata Blanco peel extract ameliorates hepatic steatosis, oxidative stress and inflammation in HF and MCD diet-induced NASH C57BL/6 J mice. J Nutr Biochem 2020;83:108426. [PMID: 32559586 DOI: 10.1016/j.jnutbio.2020.108426] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
2 Zhou Y, Yu S, Cai C, Zhong L, Yu H, Shen W. LXRɑ participates in the mTOR/S6K1/SREBP-1c signaling pathway during sodium palmitate-induced lipogenesis in HepG2 cells. Nutr Metab (Lond) 2018;15:31. [PMID: 29743930 DOI: 10.1186/s12986-018-0268-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
3 Xiao J, Xing F, Huo J, Fung ML, Liong EC, Ching YP, Xu A, Chang RC, So KF, Tipoe GL. Lycium barbarum polysaccharides therapeutically improve hepatic functions in non-alcoholic steatohepatitis rats and cellular steatosis model. Sci Rep. 2014;4:5587. [PMID: 24998389 DOI: 10.1038/srep05587] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 8.4] [Reference Citation Analysis]
4 Sasidharan SR, Joseph JA, Anandakumar S, Venkatesan V, Madhavan CN, Agarwal A. Ameliorative potential of Tamarindus indica on high fat diet induced nonalcoholic fatty liver disease in rats. ScientificWorldJournal. 2014;2014:507197. [PMID: 24688399 DOI: 10.1155/2014/507197] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
5 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016;65:1038-48. [DOI: 10.1016/j.metabol.2015.12.012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Cai J, Zhang XJ, Li H. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease. Med Res Rev. 2019;39:328-348. [PMID: 29846945 DOI: 10.1002/med.21515] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
7 Yilmaz Y, Ayyildiz T, Akin H, Colak Y, Ozturk O, Senates E, Tuncer I, Dolar E. Gallstone disease does not predict liver histology in nonalcoholic fatty liver disease. Gut Liver. 2014;8:313-317. [PMID: 24827629 DOI: 10.5009/gnl.2014.8.3.313] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
8 Ke Z, Zhao Z, Zhao Y, Xu X, Li Y, Tan S, Huang C, Zhou Z. PMFs-rich Citrus extract prevents the development of non-alcoholic fatty liver disease in C57BL/6J mice induced by a high-fat diet. Journal of Functional Foods 2018;47:28-39. [DOI: 10.1016/j.jff.2018.05.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
9 Berardo C, Di Pasqua LG, Cagna M, Richelmi P, Vairetti M, Ferrigno A. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research. Int J Mol Sci 2020;21:E9646. [PMID: 33348908 DOI: 10.3390/ijms21249646] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
10 Berk PD, Verna EC. Nonalcoholic Fatty Liver Disease: Lipids and Insulin Resistance. Clin Liver Dis. 2016;20:245-262. [PMID: 27063267 DOI: 10.1016/j.cld.2015.10.007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
11 Masarone M, Rosato V, Aglitti A, Bucci T, Caruso R, Salvatore T, Sasso FC, Tripodi MF, Persico M. Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage. PLoS One 2017;12:e0178473. [PMID: 28570615 DOI: 10.1371/journal.pone.0178473] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
12 Mullin GE. The Use of Complementary and Alternative Medicine for Liver Disease: Part I. Nutr Clin Pract 2013;28:138-9. [DOI: 10.1177/0884533612471766] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
13 Namkhah Z, Naeini F, Ostadrahimi A, Tutunchi H, Hosseinzadeh-Attar MJ. The association of the adipokine zinc-alpha2-glycoprotein with non-alcoholic fatty liver disease and related risk factors: A comprehensive systematic review. Int J Clin Pract 2021;75:e13985. [PMID: 33404166 DOI: 10.1111/ijcp.13985] [Reference Citation Analysis]
14 Pereira ENGDS, Silvares RR, Flores EEI, Rodrigues KL, Daliry A. Pyridoxamine improves metabolic and microcirculatory complications associated with nonalcoholic fatty liver disease. Microcirculation. 2020;27:e12603. [PMID: 31876010 DOI: 10.1111/micc.12603] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Losurdo G, Castellaneta A, Rendina M, Carparelli S, Leandro G, Di Leo A. Systematic review with meta-analysis: De novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther. 2018;47:704-714. [PMID: 29359341 DOI: 10.1111/apt.14521] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 5.8] [Reference Citation Analysis]
16 Bi J, Sun K, Wu H, Chen X, Tang H, Mao J. PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway. Biochem Biophys Res Commun 2018;498:1037-44. [PMID: 29550470 DOI: 10.1016/j.bbrc.2018.03.110] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
17 Chon YE, Jung KS, Kim KJ, Joo DJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Kim SU. Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci 2015;60:234-42. [PMID: 25118979 DOI: 10.1007/s10620-014-3293-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
18 Xiao J, Guo R, Fung ML, Liong EC, Tipoe GL. Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. Hepatobiliary Pancreat Dis Int. 2013;12:125-135. [PMID: 23558065 DOI: 10.1016/s1499-3872(13)60021-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
19 Soleimani D, Paknahad Z, Rouhani MH. Therapeutic Effects of Garlic on Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Patients: A Randomized Clinical Trial. Diabetes Metab Syndr Obes 2020;13:2389-97. [PMID: 32753923 DOI: 10.2147/DMSO.S254555] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
20 Rabinowich L, Shibolet O. Drug Induced Steatohepatitis: An Uncommon Culprit of a Common Disease. Biomed Res Int 2015;2015:168905. [PMID: 26273591 DOI: 10.1155/2015/168905] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 7.3] [Reference Citation Analysis]
21 Asokan SM, Wang RY, Hung TH, Lin WT. Hepato-protective effects of Glossogyne tenuifolia in Streptozotocin-nicotinamide-induced diabetic rats on high fat diet. BMC Complement Altern Med 2019;19:117. [PMID: 31170991 DOI: 10.1186/s12906-019-2529-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
22 Koplay M, Sivri M, Erdogan H, Nayman A. Importance of imaging and recent developments in diagnosis of nonalcoholic fatty liver disease. World J Hepatol 2015; 7(5): 769-776 [PMID: 25914777 DOI: 10.4254/wjh.v7.i5.769] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
23 Cigrovski Berkovic M, Virovic-Jukic L, Bilic-Curcic I, Mrzljak A. Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World J Gastroenterol 2020; 26(21): 2740-2757 [PMID: 32550751 DOI: 10.3748/wjg.v26.i21.2740] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Mirhafez SR, Azimi-Nezhad M, Dehabeh M, Hariri M, Naderan RD, Movahedi A, Abdalla M, Sathyapalan T, Sahebkar A. The Effect of Curcumin Phytosome on the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. Adv Exp Med Biol 2021;1308:25-35. [PMID: 33861434 DOI: 10.1007/978-3-030-64872-5_3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
26 Khandelwal R, Dassanayake AS, Conjeevaram HS, Singh SP. Non-alcoholic fatty liver disease in diabetes: When to refer to the hepatologist? World J Diabetes 2021; 12(9): 1479-1493 [PMID: 34630901 DOI: 10.4239/wjd.v12.i9.1479] [Reference Citation Analysis]
27 Al-Eryani L, Wahlang B, Falkner KC, Guardiola JJ, Clair HB, Prough RA, Cave M. Identification of Environmental Chemicals Associated with the Development of Toxicant-associated Fatty Liver Disease in Rodents. Toxicol Pathol 2015;43:482-97. [PMID: 25326588 DOI: 10.1177/0192623314549960] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 10.3] [Reference Citation Analysis]
28 Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36-44. [PMID: 27757953 DOI: 10.1002/path.4829] [Cited by in Crossref: 162] [Cited by in F6Publishing: 153] [Article Influence: 27.0] [Reference Citation Analysis]
29 Kessler SM, Laggai S, Van Wonterg E, Gemperlein K, Müller R, Haybaeck J, Vandenbroucke RE, Ogris M, Libert C, Kiemer AK. Transient Hepatic Overexpression of Insulin-Like Growth Factor 2 Induces Free Cholesterol and Lipid Droplet Formation. Front Physiol 2016;7:147. [PMID: 27199763 DOI: 10.3389/fphys.2016.00147] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
30 Dvorak K, Hainer R, Petrtyl J, Zeman M, Vareka T, Zak A, Sroubkova R, Svestka T, Vitek L, Bruha R. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015;159:442-8. [PMID: 25004910 DOI: 10.5507/bp.2014.033] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
31 Cocciolillo S, Parruti G, Marzio L. CEUS and Fibroscan in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. World J Hepatol 2014; 6(7): 496-503 [PMID: 25068001 DOI: 10.4254/wjh.v6.i7.496] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
32 Paz-Filho G, Mastronardi CA, Parker BJ, Khan A, Inserra A, Matthaei KI, Ehrhart-Bornstein M, Bornstein S, Wong ML, Licinio J. Molecular pathways involved in the improvement of non-alcoholic fatty liver disease. J Mol Endocrinol 2013;51:167-79. [PMID: 23718963 DOI: 10.1530/JME-13-0072] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
33 Petrtýl J, Dvořák K, Stříteský J, Leníček M, Jirásková A, Šmíd V, Haluzík M, Brůha R, Vítek L. Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants (Basel) 2021;10:2000. [PMID: 34943103 DOI: 10.3390/antiox10122000] [Reference Citation Analysis]
34 Arshad MS, Imran M, Ahmed A, Sohaib M, Ullah A, Nisa MU, Hina G, Khalid W, Rehana H. Tamarind: A diet-based strategy against lifestyle maladies. Food Sci Nutr 2019;7:3378-90. [PMID: 31762991 DOI: 10.1002/fsn3.1218] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Chao CY, Battat R, Al Khoury A, Restellini S, Sebastiani G, Bessissow T. Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article. World J Gastroenterol 2016; 22(34): 7727-7734 [PMID: 27678354 DOI: 10.3748/wjg.v22.i34.7727] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 6.0] [Reference Citation Analysis]
36 Xiao J, Fai So K, Liong EC, Tipoe GL. Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. J Tradit Complement Med 2013;3:88-94. [PMID: 24716162 DOI: 10.4103/2225-4110.110411] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.9] [Reference Citation Analysis]
37 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol 2016; 7(2): 211-217 [PMID: 27190693 DOI: 10.4291/wjgp.v7.i2.211] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
38 Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, McMahan RH, Abdelmalek MF, Rosen HR, Jackman MR, MacLean PS, Diggle CP, Asipu A, Inaba S, Kosugi T, Sato W, Maruyama S, Sánchez-Lozada LG, Sautin YY, Hill JO, Bonthron DT, Johnson RJ. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology 2013;58:1632-43. [PMID: 23813872 DOI: 10.1002/hep.26594] [Cited by in Crossref: 164] [Cited by in F6Publishing: 157] [Article Influence: 18.2] [Reference Citation Analysis]
39 Wu G, Li H, Fang Q, Zhang J, Zhang M, Zhang L, Wu L, Hou X, Lu J, Bao Y, Jia W. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease. Sci Rep 2017;7:5095. [PMID: 28698650 DOI: 10.1038/s41598-017-05257-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
40 Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2015;1852:1765-78. [DOI: 10.1016/j.bbadis.2015.05.015] [Cited by in Crossref: 127] [Cited by in F6Publishing: 134] [Article Influence: 18.1] [Reference Citation Analysis]
41 Vizuete J, Camero A, Malakouti M, Garapati K, Gutierrez J. Perspectives on Nonalcoholic Fatty Liver Disease: An Overview of Present and Future Therapies. J Clin Transl Hepatol 2017;5:67-75. [PMID: 28507929 DOI: 10.14218/JCTH.2016.00061] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
42 Bao L, Yin J, Gao W, Wang Q, Yao W, Gao X. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. Br J Pharmacol. 2018;175:3379-3393. [PMID: 29859019 DOI: 10.1111/bph.14383] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
43 Loffredo L, Del Ben M, Perri L, Carnevale R, Nocella C, Catasca E, Baratta F, Ceci F, Polimeni L, Gozzo P, Violi F, Angelico F. Effects of dark chocolate on NOX-2-generated oxidative stress in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2016;44:279-86. [PMID: 27265388 DOI: 10.1111/apt.13687] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
44 Pérez-garcía A, Dongil P, Hurtado-carneiro V, Blázquez E, Sanz C, Álvarez E. High-fat diet alters PAS kinase regulation by fasting and feeding in liver. The Journal of Nutritional Biochemistry 2018;57:14-25. [DOI: 10.1016/j.jnutbio.2018.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
45 Arconzo M, Piccinin E, Moschetta A. Increased risk of acute liver failure by pain killer drugs in NAFLD: Focus on nuclear receptors and their coactivators. Dig Liver Dis 2021;53:26-34. [PMID: 32546444 DOI: 10.1016/j.dld.2020.05.034] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Nassir F, Ibdah JA. Role of mitochondria in nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:8713-8742. [PMID: 24837835 DOI: 10.3390/ijms15058713] [Cited by in Crossref: 148] [Cited by in F6Publishing: 141] [Article Influence: 18.5] [Reference Citation Analysis]
47 Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017;66:2055-2065. [PMID: 28777879 DOI: 10.1002/hep.29420] [Cited by in Crossref: 98] [Cited by in F6Publishing: 89] [Article Influence: 19.6] [Reference Citation Analysis]
48 Bjørndal B, Alterås EK, Lindquist C, Svardal A, Skorve J, Berge RK. Associations between fatty acid oxidation, hepatic mitochondrial function, and plasma acylcarnitine levels in mice. Nutr Metab (Lond) 2018;15:10. [PMID: 29422939 DOI: 10.1186/s12986-018-0241-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
49 Banini BA, Sanyal AJ. Nonalcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, Natural History, Diagnosis, and Current Treatment Options. Clin Med Insights Ther 2016;8:75-84. [PMID: 28670148 DOI: 10.4137/cmt.s18885] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
50 Purnak T, Yilmaz Y. Liver disease and malnutrition. Best Pract Res Clin Gastroenterol. 2013;27:619-629. [PMID: 24090946 DOI: 10.1016/j.bpg.2013.06.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
51 Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871. [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044] [Cited by in Crossref: 223] [Cited by in F6Publishing: 203] [Article Influence: 24.8] [Reference Citation Analysis]
52 Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci 2018;14:1233-44. [PMID: 30393477 DOI: 10.5114/aoms.2017.68821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
53 Ocker M. Challenges and opportunities in drug development for nonalcoholic steatohepatitis. Eur J Pharmacol 2020;870:172913. [PMID: 31926994 DOI: 10.1016/j.ejphar.2020.172913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
54 Yilmaz Y, Senates E, Yesil A, Ergelen R, Colak Y. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease. J Diabetes Complications 2014;28:328-31. [PMID: 24602757 DOI: 10.1016/j.jdiacomp.2014.01.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
55 Khajehahmadi Z, Mohagheghi S, Nikeghbalian S, Geramizadeh B, Khodadadi I, Karimi J, Ghaffari ME, Tavilani H. Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: Is TAZ a crucial regulator? IUBMB Life 2019;71:1382-90. [PMID: 31087761 DOI: 10.1002/iub.2068] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
56 Mishra A, Iyer S, Kesarwani A, Baligar P, Arya SP, Arindkar S, Kumar MJ, Upadhyay P, Majumdar SS, Nagarajan P. Role of antigen presenting cell invariant chain in the development of hepatic steatosis in mouse model. Exp Cell Res 2016;346:188-97. [PMID: 27371158 DOI: 10.1016/j.yexcr.2016.06.019] [Reference Citation Analysis]
57 Eriksen PL, Thomsen KL, Larsen LP, Grønbaek H, Vilstrup H, Sørensen M. Non-alcoholic steatohepatitis, but not simple steatosis, disturbs the functional homogeneity of the liver - a human galactose positron emission tomography study. Aliment Pharmacol Ther 2019;50:84-92. [DOI: 10.1111/apt.15293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
58 Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H, Yang QB, Hu H. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therap Adv Gastroenterol 2019;12:1756284819878046. [PMID: 31598135 DOI: 10.1177/1756284819878046] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
59 Zhou YY, Zhou XD, Wu SJ, Fan DH, Van Poucke S, Chen YP, Fu SW, Zheng MH. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis. Hepatol Commun 2018;2:376-92. [PMID: 29619417 DOI: 10.1002/hep4.1155] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
60 Saadati S, Hatami B, Yari Z, Shahrbaf MA, Eghtesad S, Mansour A, Poustchi H, Hedayati M, Aghajanpoor-Pasha M, Sadeghi A, Hekmatdoost A. The effects of curcumin supplementation on liver enzymes, lipid profile, glucose homeostasis, and hepatic steatosis and fibrosis in patients with non-alcoholic fatty liver disease. Eur J Clin Nutr 2019;73:441-9. [PMID: 30610213 DOI: 10.1038/s41430-018-0382-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
61 Walenbergh SM, Houben T, Rensen SS, Bieghs V, Hendrikx T, van Gorp PJ, Oligschlaeger Y, Jeurissen ML, Gijbels MJ, Buurman WA, Vreugdenhil AC, Greve JW, Plat J, Hofker MH, Kalhan S, Pihlajamäki J, Lindsey P, Koek GH, Shiri-Sverdlov R. Plasma cathepsin D correlates with histological classifications of fatty liver disease in adults and responds to intervention. Sci Rep 2016;6:38278. [PMID: 27922112 DOI: 10.1038/srep38278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
62 Shi KQ, Tang JZ, Zhu XL, Ying L, Li DW, Gao J, Fang YX, Li GL, Song YJ, Deng ZJ, Wu JM, Tang KF. Controlled attenuation parameter for the detection of steatosis severity in chronic liver disease: a meta-analysis of diagnostic accuracy. J Gastroenterol Hepatol. 2014;29:1149-1158. [PMID: 24476011 DOI: 10.1111/jgh.12519] [Cited by in Crossref: 89] [Cited by in F6Publishing: 73] [Article Influence: 11.1] [Reference Citation Analysis]
63 Shao N, Yu XY, Ma XF, Lin WJ, Hao M, Kuang HY. Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway. Gastroenterol Res Pract 2018;2018:1864307. [PMID: 29849583 DOI: 10.1155/2018/1864307] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
64 Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 2016;11:3-10. [PMID: 26602387 DOI: 10.1007/s11739-015-1346-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
65 Feldman A, Aigner E, Weghuber D, Paulmichl K. The Potential Role of Iron and Copper in Pediatric Obesity and Nonalcoholic Fatty Liver Disease. Biomed Res Int. 2015;2015:287401. [PMID: 26273604 DOI: 10.1155/2015/287401] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
66 Bedogni G, Nobili V, Tiribelli C. Epidemiology of fatty liver: An update. World J Gastroenterol 2014; 20(27): 9050-9054 [PMID: 25083078 DOI: 10.3748/wjg.v20.i27.9050] [Cited by in F6Publishing: 42] [Reference Citation Analysis]
67 Kelley CE, Brown AJ, Diehl AM, Setji TL. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. World J Gastroenterol 2014; 20(39): 14172-14184 [PMID: 25339805 DOI: 10.3748/wjg.v20.i39.14172] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
68 Kuraji R, Sekino S, Kapila Y, Numabe Y. Periodontal disease-related nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: An emerging concept of oral-liver axis. Periodontol 2000 2021;87:204-40. [PMID: 34463983 DOI: 10.1111/prd.12387] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Matsushita N, Osaka T, Haruta I, Ueshiba H, Yanagisawa N, Omori-Miyake M, Hashimoto E, Shibata N, Tokushige K, Saito K. Effect of Lipopolysaccharide on the Progression of Non-Alcoholic Fatty Liver Disease in High Caloric Diet-Fed Mice. Scand J Immunol. 2016;83:109-118. [PMID: 26524607 DOI: 10.1111/sji.12397] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
70 Mazzoccoli G, De Cosmo S, Mazza T. The Biological Clock: A Pivotal Hub in Non-alcoholic Fatty Liver Disease Pathogenesis. Front Physiol 2018;9:193. [PMID: 29662454 DOI: 10.3389/fphys.2018.00193] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
71 Ebert T, Linder N, Schaudinn A, Busse H, Berger J, Lichtinghagen R, Keim V, Wiegand J, Karlas T. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. Endocrine 2017;58:246-52. [DOI: 10.1007/s12020-017-1417-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
72 Bernsmeier C, Meyer-Gerspach AC, Blaser LS, Jeker L, Steinert RE, Heim MH, Beglinger C. Glucose-induced glucagon-like Peptide 1 secretion is deficient in patients with non-alcoholic fatty liver disease. PLoS One 2014;9:e87488. [PMID: 24489924 DOI: 10.1371/journal.pone.0087488] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 7.3] [Reference Citation Analysis]
73 Ngu JH, Goh GB, Poh Z, Soetikno R. Managing non-alcoholic fatty liver disease. Singapore Med J 2016;57:368-71. [PMID: 27439352 DOI: 10.11622/smedj.2016119] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
74 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
75 Verhaegh P, Wisse E, de Munck T, Greve JW, Verheij J, Riedl R, Duimel H, Masclee A, Jonkers D, Koek G. Electron microscopic observations in perfusion-fixed human non-alcoholic fatty liver disease biopsies. Pathology 2021;53:220-8. [PMID: 33143903 DOI: 10.1016/j.pathol.2020.07.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
76 Fielding CM, Angulo P. Hepatic steatosis and steatohepatitis: Are they really two distinct entities? Curr Hepatol Rep 2014;13:151-8. [PMID: 24977111 DOI: 10.1007/s11901-014-0227-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
77 Karlas T, Wiegand J, Berg T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best Pract Res Clin Endocrinol Metab. 2013;27:195-208. [PMID: 23731881 DOI: 10.1016/j.beem.2013.02.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 5.4] [Reference Citation Analysis]
78 Heeba GH, Morsy MA. Fucoidan ameliorates steatohepatitis and insulin resistance by suppressing oxidative stress and inflammatory cytokines in experimental non-alcoholic fatty liver disease. Environ Toxicol Pharmacol. 2015;40:907-914. [PMID: 26498267 DOI: 10.1016/j.etap.2015.10.003] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 6.3] [Reference Citation Analysis]
79 Anavi S, Ni Z, Tirosh O, Fedorova M. Steatosis-induced proteins adducts with lipid peroxidation products and nuclear electrophilic stress in hepatocytes. Redox Biol 2015;4:158-68. [PMID: 25560244 DOI: 10.1016/j.redox.2014.12.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
80 Namkhah Z, Naeini F, Mahdi Rezayat S, Mehdi Yaseri, Mansouri S, Javad Hosseinzadeh-Attar M. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial. Int J Clin Pract 2021;75:e14852. [PMID: 34516703 DOI: 10.1111/ijcp.14852] [Reference Citation Analysis]
81 Haufe S, Haas V, Utz W, Birkenfeld AL, Jeran S, Böhnke J, Mähler A, Luft FC, Schulz-Menger J, Boschmann M, Jordan J, Engeli S. Long-lasting improvements in liver fat and metabolism despite body weight regain after dietary weight loss. Diabetes Care 2013;36:3786-92. [PMID: 23963894 DOI: 10.2337/dc13-0102] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
82 Maeda T, Miki S, Morihara N, Kagawa Y. Aged garlic extract ameliorates fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance. Exp Ther Med 2019;18:857-66. [PMID: 31281460 DOI: 10.3892/etm.2019.7636] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
83 Liu Z, Liu W, Huang Y, Guo J, Zhao R, Yang X. Lipopolysaccharide significantly influences the hepatic triglyceride metabolism in growing pigs. Lipids Health Dis 2015;14:64. [PMID: 26121977 DOI: 10.1186/s12944-015-0064-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
84 Sheng G, Xie Q, Wang R, Hu C, Zhong M, Zou Y. Waist-to-height ratio and non-alcoholic fatty liver disease in adults. BMC Gastroenterol 2021;21:239. [PMID: 34034671 DOI: 10.1186/s12876-021-01824-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
85 Lepreux S, Villeneuve J, Dewitte A, Bérard AM, Desmoulière A, Ripoche J. CD40 signaling and hepatic steatosis: Unanticipated links. Clin Res Hepatol Gastroenterol 2017;41:357-69. [PMID: 27989689 DOI: 10.1016/j.clinre.2016.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 63] [Article Influence: 11.7] [Reference Citation Analysis]
87 Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73:1969-1987. [PMID: 26894897 DOI: 10.1007/s00018-016-2161-x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 15.2] [Reference Citation Analysis]
88 Hong M, Hwang JT, Shin EJ, Hur HJ, Kang K, Choi HK, Chung MY, Chung S, Sung MJ, Park JH. Genome-wide analysis of DNA methylation identifies novel differentially methylated regions associated with lipid accumulation improved by ethanol extracts of Allium tubersosum and Capsella bursa-pastoris in a cell model. PLoS One 2019;14:e0217877. [PMID: 31170227 DOI: 10.1371/journal.pone.0217877] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
89 Shih KL, Su WW, Chang CC, Kor CT, Chou CT, Chen TY, Wu HM. Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:24031. [PMID: 27079922 DOI: 10.1038/srep24031] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
90 Dall M, Penke M, Sulek K, Matz-Soja M, Holst B, Garten A, Kiess W, Treebak JT. Hepatic NAD+ levels and NAMPT abundance are unaffected during prolonged high-fat diet consumption in C57BL/6JBomTac mice. Mol Cell Endocrinol 2018;473:245-56. [PMID: 29408602 DOI: 10.1016/j.mce.2018.01.025] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
91 Spremović Rađenović S, Pupovac M, Andjić M, Bila J, Srećković S, Gudović A, Dragaš B, Radunović N. Prevalence, Risk Factors, and Pathophysiology of Nonalcoholic Fatty Liver Disease (NAFLD) in Women with Polycystic Ovary Syndrome (PCOS). Biomedicines 2022;10:131. [DOI: 10.3390/biomedicines10010131] [Reference Citation Analysis]
92 Van De Wier B, Koek GH, Bast A, Haenen GRMM. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Critical Reviews in Food Science and Nutrition 2015;57:834-55. [DOI: 10.1080/10408398.2014.952399] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 11.0] [Reference Citation Analysis]
93 Mangge H, Baumgartner BG, Zelzer S, Prüller F, Schnedl WJ, Reininghaus EZ, Haybaeck J, Lackner C, Stauber R, Aigner E, Weghuber D. Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages. Aliment Pharmacol Ther 2015;42:99-105. [DOI: 10.1111/apt.13232] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
94 Chiang W, Shibu MA, Lee K, Wu J, Tsai F, Pan L, Huang C, Lin W. Lipolysis-stimulating peptide-VHVV ameliorates high fat diet induced hepatocyte apoptosis and fibrosis. Journal of Functional Foods 2014;11:482-92. [DOI: 10.1016/j.jff.2014.08.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
95 Chiang WD, Huang CY, Paul CR, Lee ZY, Lin WT. Lipolysis stimulating peptides of potato protein hydrolysate effectively suppresses high-fat-diet-induced hepatocyte apoptosis and fibrosis in aging rats. Food Nutr Res 2016;60:31417. [PMID: 27415158 DOI: 10.3402/fnr.v60.31417] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
96 Zhang J, Zhao Y, Xu C, Hong Y, Lu H, Wu J, Chen Y. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep. 2014;4:5832. [PMID: 25060337 DOI: 10.1038/srep05832] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 9.0] [Reference Citation Analysis]
97 Holterman A, Gurria J, Tanpure S, Disomma N. Nonalcoholic fatty liver disease and bariatric surgery in adolescents. Seminars in Pediatric Surgery 2014;23:49-57. [DOI: 10.1053/j.sempedsurg.2013.10.016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
98 Hormoznejad R, Mohammad Shahi M, Rahim F, Helli B, Alavinejad P, Sharhani A. Combined cranberry supplementation and weight loss diet in non-alcoholic fatty liver disease: a double-blind placebo-controlled randomized clinical trial. Int J Food Sci Nutr 2020;71:991-1000. [PMID: 32237922 DOI: 10.1080/09637486.2020.1746957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Chakravarthy MV, Neuschwander-Tetri BA. The metabolic basis of nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00112. [PMID: 33102794 DOI: 10.1002/edm2.112] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
100 Sunbul M, Agirbasli M, Durmus E, Kivrak T, Akin H, Aydin Y, Ergelen R, Yilmaz Y. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. 2014;237:490-493. [PMID: 25463079 DOI: 10.1016/j.atherosclerosis.2014.10.004] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 5.3] [Reference Citation Analysis]
101 Jung DH, Lee YJ, Park B. Joint Effect of Hepatic Steatosis and Alanine Aminotransferase Within the Normal Range on Incident Ischemic Heart Disease: A Prospective Study in Koreans. Clin Interv Aging 2021;16:513-23. [PMID: 33790546 DOI: 10.2147/CIA.S301741] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Yoo J, Cho I, Jeong I, Ahn KJ, Chung HY, Hwang Y. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation. Toxicology and Applied Pharmacology 2018;360:18-29. [DOI: 10.1016/j.taap.2018.09.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
103 Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179:16-29. [PMID: 29235656 DOI: 10.1111/bjd.16239] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
104 Reis-Júnior P, Tanigawa R, de Mesquita GHA, Basan N, Alves V, D'Albuquerque LAC, Andraus W. Steatosis and steatohepatitis found in adults after death due to non-burn trauma. Clinics (Sao Paulo) 2019;74:e1070. [PMID: 31618320 DOI: 10.6061/clinics/2019/e1070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Baselga-escudero L, Souza-mello V, Pascual-serrano A, Rachid T, Voci A, Demori I, Grasselli E. Beneficial effects of the Mediterranean spices and aromas on non-alcoholic fatty liver disease. Trends in Food Science & Technology 2017;61:141-59. [DOI: 10.1016/j.tifs.2016.11.019] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
106 Yao Z, Liu XC, Gu YE. Schisandra chinensis Baill, a Chinese medicinal herb, alleviates high-fat-diet-inducing non-alcoholic steatohepatitis in rats. Afr J Tradit Complement Altern Med 2014;11:222-7. [PMID: 24653581 DOI: 10.4314/ajtcam.v11i1.35] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
107 Figueiredo LS, Oliveira KM, Freitas IN, Silva JA Jr, Silva JN, Favero-Santos BC, Bonfleur ML, Carneiro EM, Ribeiro RA. Bisphenol-A exposure worsens hepatic steatosis in ovariectomized mice fed on a high-fat diet: Role of endoplasmic reticulum stress and fibrogenic pathways. Life Sci 2020;256:118012. [PMID: 32593710 DOI: 10.1016/j.lfs.2020.118012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
108 Rosso N, Chavez-Tapia NC, Tiribelli C, Bellentani S. Translational approaches: From fatty liver to non-alcoholic steatohepatitis. World J Gastroenterol 2014; 20(27): 9038-9049 [PMID: 25083077 DOI: 10.3748/wjg.v20.i27.9038] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
109 Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038-1048. [PMID: 26823198 DOI: 10.1016/j.metabol.2015.12.012] [Cited by in Crossref: 901] [Cited by in F6Publishing: 867] [Article Influence: 150.2] [Reference Citation Analysis]
110 Lim JW, Dillon J, Miller M. Proteomic and genomic studies of non-alcoholic fatty liver disease - clues in the pathogenesis. World J Gastroenterol 2014; 20(26): 8325-8340 [PMID: 25024592 DOI: 10.3748/wjg.v20.i26.8325] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
111 Dogru T, Genc H, Ercin CN. Carotid atherosclerosis or nonalcoholic fatty liver disease: Which comes first? Atherosclerosis 2013;231:187-8. [DOI: 10.1016/j.atherosclerosis.2013.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
112 Martín-Pozuelo G, González-Barrio R, Barberá GG, Albalat A, García-Alonso J, Mullen W, Mischak H, Periago MJ. Tomato Juice Consumption Modifies the Urinary Peptide Profile in Sprague-Dawley Rats with Induced Hepatic Steatosis. Int J Mol Sci 2016;17:E1789. [PMID: 27792191 DOI: 10.3390/ijms17111789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
113 Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019;76:99-128. [PMID: 30343320 DOI: 10.1007/s00018-018-2947-0] [Cited by in Crossref: 109] [Cited by in F6Publishing: 118] [Article Influence: 27.3] [Reference Citation Analysis]
114 Abenavoli L, Milic N, Masarone M, Persico M. Association between non-alcoholic fatty liver disease, insulin resistance and Helicobacter pylori. Med Hypotheses. 2013;81:913-915. [PMID: 24011768 DOI: 10.1016/j.mehy.2013.08.011] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
115 Chen W, Zhang J, Fan HN, Zhu JS. Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2018;11:1756284818815184. [PMID: 30574191 DOI: 10.1177/1756284818815184] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
116 Alam S, Mustafa G, Alam M, Ahmad N. Insulin resistance in development and progression of nonalcoholic fatty liver disease. World J Gastrointest Pathophysiol. 2016;7:211-217. [PMID: 27190693 DOI: 10.3349/ymj.2016.57.4.885] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
117 Virarkar M, Szklaruk J, Jensen CT, Taggart MW, Bhosale P. What's New in Hepatic Steatosis. Semin Ultrasound CT MR 2021;42:405-15. [PMID: 34130852 DOI: 10.1053/j.sult.2021.03.001] [Reference Citation Analysis]
118 Del Ben M, Polimeni L, Carnevale R, Bartimoccia S, Nocella C, Baratta F, Loffredo L, Pignatelli P, Violi F, Angelico F. NOX2-generated oxidative stress is associated with severity of ultrasound liver steatosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2014;14:81. [PMID: 24758604 DOI: 10.1186/1471-230x-14-81] [Cited by in Crossref: 49] [Cited by in F6Publishing: 29] [Article Influence: 6.1] [Reference Citation Analysis]
119 Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837-843. [PMID: 25311610 DOI: 10.1016/j.nutres.2014.09.005] [Cited by in Crossref: 167] [Cited by in F6Publishing: 155] [Article Influence: 20.9] [Reference Citation Analysis]
120 Mallick P, Shah P, Gandhi A, Ghose R. Impact of obesity on accumulation of the toxic irinotecan metabolite, SN-38, in mice. Life Sci 2015;139:132-8. [PMID: 26334566 DOI: 10.1016/j.lfs.2015.08.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
121 Liu W, Ye C, Cheng Q, Zhang X, Yao L, Li Q, Huang J, Liu Y, Zou Z, Wang H, Yan J, Zhu Y, Wang C, Ai D. Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis. Cell Mol Gastroenterol Hepatol 2019;7:211-31. [PMID: 30539788 DOI: 10.1016/j.jcmgh.2018.09.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
122 Chuang HL, Baskaran R, Hsuan Day C, Lin YM, Ho CC, Ho TJ, Chen RJ, Mahalakshmi BK, Kuo WW, Huang CY. Role of potato protein hydrolysate and exercise in preventing high-fat diet-induced hepatocyte apoptosis in senescence-accelerated mouse. J Food Biochem 2020;44:e13525. [PMID: 33078424 DOI: 10.1111/jfbc.13525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Jung KS, Kim BK, Kim SU, Chon YE, Chun KH, Kim SB, Lee SH, Ahn SS, Park JY, Kim DY. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS One. 2014;9:e98689. [PMID: 24901649 DOI: 10.1371/journal.pone.0098689] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
124 El-Sherbiny M, Eldosoky M, El-Shafey M, Othman G, Elkattawy HA, Bedir T, Elsherbiny NM. Vitamin D nanoemulsion enhances hepatoprotective effect of conventional vitamin D in rats fed with a high-fat diet. Chem Biol Interact 2018;288:65-75. [PMID: 29653100 DOI: 10.1016/j.cbi.2018.04.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
125 Liu Q, Niu CY. From "two hit theory" to "multiple hit theory": Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(19): 1171-1178 [DOI: 10.11569/wcjd.v27.i19.1171] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
126 Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796-803. [PMID: 26234526 DOI: 10.1017/s0007114515002433] [Cited by in Crossref: 89] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
127 Yang X, Mo W, Zheng C, Li W, Tang J, Wu X. Alleviating effects of noni fruit polysaccharide on hepatic oxidative stress and inflammation in rats under a high-fat diet and its possible mechanisms. Food Funct 2020;11:2953-68. [PMID: 32315005 DOI: 10.1039/d0fo00178c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]